Patents by Inventor Bernard Mahon

Bernard Mahon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
    Patent number: 11819545
    Abstract: The present invention relates to a live attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Grant
    Filed: August 2, 2021
    Date of Patent: November 21, 2023
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanagh
  • Vaccine for Prophylaxis or Treatment of an Allergen-Driven Airway Pathology
    Publication number: 20210361759
    Abstract: The present invention relates to a live attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Application
    Filed: August 2, 2021
    Publication date: November 25, 2021
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanagh
  • Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
    Patent number: 11110161
    Abstract: The present invention relates to a live attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: September 7, 2021
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanagh
  • Vaccine for Prophylaxis or Treatment of an Allergen-Driven Airway Pathology
    Publication number: 20200282041
    Abstract: The present invention relates to a live attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Application
    Filed: April 3, 2020
    Publication date: September 10, 2020
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanagh
  • Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
    Patent number: 10653765
    Abstract: The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: May 19, 2020
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanagh
  • Vaccine for Prophylaxis or Treatment of an Allergen-Driven Airway Pathology
    Publication number: 20190358309
    Abstract: The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Application
    Filed: August 9, 2019
    Publication date: November 28, 2019
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanagh
  • Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
    Patent number: 10420827
    Abstract: The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: September 24, 2019
    Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur de Lille, National University of Ireland Maynooth
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanaugh
  • Vaccine for Prophylaxis or Treatment of an Allergen-Driven Airway Pathology
    Publication number: 20180085450
    Abstract: The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Application
    Filed: November 1, 2017
    Publication date: March 29, 2018
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanagh
  • Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
    Patent number: 9839683
    Abstract: The present invention relates to a live attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: December 12, 2017
    Assignees: Institut National de la Sante et de la Recherche Medicale, Institut Pasteur de Lille, National University of Ireland Maynooth
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanagh
  • Vaccine for Prophylaxis or Treatment of an Allergen-Driven Airway Pathology
    Publication number: 20150182614
    Abstract: The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Application
    Filed: January 30, 2015
    Publication date: July 2, 2015
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanagh
  • Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
    Patent number: 8986709
    Abstract: The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: March 24, 2015
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Institut Pasteur de Lille, National University of Ireland Maynooth
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanagh
  • Vaccine for Prophylaxis or Treatment of an Allergen-Driven Airway Pathology
    Publication number: 20130183336
    Abstract: The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Application
    Filed: March 1, 2013
    Publication date: July 18, 2013
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), National University of Ireland Maynooth, Institut Pasteur de Lille
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanagh
  • Vaccine for Prophylaxis or Treatment of an Allergen-Driven Airway Pathology
    Publication number: 20120177688
    Abstract: The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Application
    Filed: April 26, 2010
    Publication date: July 12, 2012
    Applicants: INSTITUT PASTEUR DE LILLE, INSERM (Institu National de la Sante et de la Recherche Medicale), NATIONAL UNIVERSITY OF IRELAND MAYNOOTH
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanagh
  • IL-12 as an adjuvant for Bordetella pertussis vaccines
    Publication number: 20060263379
    Abstract: This invention provides a composition of at least one Bordetella antigen and an effective adjuvant amount of interleukin-12 (IL-12), and uses thereof as a vaccine against Bordetella infection. Methods for using IL-12 as an adjuvant in combination with vaccines against Bordetella are also provided.
    Type: Application
    Filed: July 27, 2006
    Publication date: November 23, 2006
    Applicant: National University of Ireland
    Inventors: Kingston Mills, Bernard Mahon, Mark Ryan, Fiona Griffin
  • IL-12 as an adjuvant for Bordetella pertussis vaccines
    Publication number: 20060263380
    Abstract: This invention provides a composition of at least one Bordetella antigen and an effective adjuvant amount of interleukin-12 (IL-12), and uses thereof as a vaccine against Bordetella infection. Methods for using IL-12 as an adjuvant in combination with vaccines against Bordetella are also provided.
    Type: Application
    Filed: July 27, 2006
    Publication date: November 23, 2006
    Applicant: National University of Ireland
    Inventors: Kingston Mills, Bernard Mahon, Marks Ryan, Fiona Griffin
  • IL-12 as an adjuvant for Bordetella Pertussis vaccines
    Publication number: 20060257419
    Abstract: This invention provides a composition of at least one Bordetella antigen and an effective adjuvant amount of interleukin-12 (IL-12), and uses thereof as a vaccine against Bordetella infection. Methods for using IL-12 as an adjuvant in combination with vaccines against Bordetella are also provided.
    Type: Application
    Filed: July 27, 2006
    Publication date: November 16, 2006
    Applicant: National University of Ireland
    Inventors: Kingston Mills, Bernard Mahon, Mark Ryan, Fiona Griffin
  • IL-12 an adjuvant for bordetella pertussis vaccines
    Publication number: 20050158276
    Abstract: This invention provides a composition of at least one Bordetella antigen and an effective adjuvant amount of interleukin-12 (IL-12), and uses thereof as a vaccine against Bordetella infection. Methods for using IL-12 as an adjuvant in combination with vaccines against Bordetella are also provided.
    Type: Application
    Filed: March 4, 2005
    Publication date: July 21, 2005
    Applicant: National University of Ireland
    Inventors: Kingston Mills, Bernard Mahon, Mark Rvan, Fiona Griffin